Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM
Nature Communications, 2021 Systemic AL amyloidosis is a rare disease that is caused by the misfolding of immunoglobulin light chains (LCs). Potential drivers of amyloid formation in this disease are post-translational modifications (PTMs) and the mutational changes that are ...
L. Radamaker +17 more
semanticscholar +1 more source
Prognosis and Staging of AL Amyloidosis [PDF]
Acta Haematologica, 2020 The treatment options for systemic light chain amyloidosis (AL) are currently widening in an unprecedented way, brought about by an expanding arsenal of anti-myeloma therapy as well as by novel approaches to target toxic light chains and, most recently, deposited amyloid directly.
Tobias Dittrich +3 more
openaire +2 more sources
Strong positive light chain immunostaining in a patient with transthyretin amyloidosis
Hematology, 2023 The two most common systemic amyloidosis types are immunoglobulin light chain (AL) and amyloid transthyretin (ATTR) amyloidosis, in which the precursor proteins responsible for amyloidosis are light chain and transthyretin, respectively.
Jiao Chen +5 more
doaj +1 more source
Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome [PDF]
, 2013 Background Cardiac amyloidosis is a fatal disease whose prognosis and treatment rely on identification of the amyloid type. In our aging population transthyretin amyloidosis (ATTRwt) is common and must be differentiated from other amyloid types.
Banypersad, SM +15 more
core +1 more source
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis
Amyloid: Journal of Protein Folding Disorders, 2021 In 2012, the International Society of Amyloidosis (ISA) established the criteria for assessment of haematologic response to treatment in light chain (AL) amyloidosis [1].
G. Palladini +10 more
semanticscholar +1 more source
Dysregulation of miRNAs In AL Amyloidosis [PDF]
Blood, 2010 Abstract Abstract 4648 Bone marrow plasma cells (BMPC) were purified from aspirates obtained from patients with AL amyloidosis using anti-CD138 immunomagnetic beads, and from controls. Expression levels of micro RNAs (miRNAs) were compared by microarray.
Carl O'Hara +5 more
openaire +4 more sources
Evaluation of peripheral amyloid neuropathy
Неврология, нейропсихиатрия, психосоматика, 2021 Symptoms of peripheral nervous system (PNS) damage are common clinical manifestations of systemic amyloidosis. Peripheral amyloid neuropathy is characterized by a progressive course, leading to the disability of patients; however, the current ...
O. E. Zinovyeva +4 more
doaj +1 more source
Severe Obstructive Cholestasis and Hypercalcemia Caused by Light-Chain Amyloidosis: A Case Report [PDF]
Iranian Journal of Medical Sciences, 2022 Gastrointestinal amyloidosis is a condition caused by the deposition of extracellular protein fragments. It can be associated with complex and diverse pathways and can have numerous manifestations and etiologies.
Zahra Davoudi +3 more
doaj +1 more source
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis [PDF]
, 2016 Amyloid light-chain (LC) amyloidosis (AL amyloidosis) is a rare and fatal disease for which there are no approved therapies. In patients with AL amyloidosis, LC aggregates progressively accumulate in organs, resulting in organ failure that is ...
Ando, Y +10 more
core +1 more source
AL amyloidosis enhances development of amyloid A amyloidosis [PDF]
British Journal of Dermatology, 2007 Contains fulltext : 52125.pdf (Publisher’s version ) (Open Access)
Hilst, J.C.H. van der +3 more
openaire +2 more sources